JP2022502476A - インドールａｈｒ阻害剤およびその使用 - Google Patents
インドールａｈｒ阻害剤およびその使用 Download PDFInfo
- Publication number
- JP2022502476A JP2022502476A JP2021521024A JP2021521024A JP2022502476A JP 2022502476 A JP2022502476 A JP 2022502476A JP 2021521024 A JP2021521024 A JP 2021521024A JP 2021521024 A JP2021521024 A JP 2021521024A JP 2022502476 A JP2022502476 A JP 2022502476A
- Authority
- JP
- Japan
- Prior art keywords
- iii
- cancer
- pharmaceutically acceptable
- ring
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC1C(C(*=C)=*)=CCC1 Chemical compound CC1C(C(*=C)=*)=CCC1 0.000 description 39
- XNCZCRHGSHZHCF-UHFFFAOYSA-N CC(C)c(cn[n]12)c1nc(-c1cc(F)cnc1)nc2Cl Chemical compound CC(C)c(cn[n]12)c1nc(-c1cc(F)cnc1)nc2Cl XNCZCRHGSHZHCF-UHFFFAOYSA-N 0.000 description 2
- LJWYBCXJJVUBAZ-UHFFFAOYSA-N NC(CC1)Cc2c1[nH]c(cc1)c2cc1O Chemical compound NC(CC1)Cc2c1[nH]c(cc1)c2cc1O LJWYBCXJJVUBAZ-UHFFFAOYSA-N 0.000 description 2
- NKJIYYDCYKUWNB-UHFFFAOYSA-N Brc1ccc(N2CCOCC2)nc1 Chemical compound Brc1ccc(N2CCOCC2)nc1 NKJIYYDCYKUWNB-UHFFFAOYSA-N 0.000 description 1
- HYKFPJAARRNNRX-TVKKRMFBSA-N C1CC2c(cccc3)c3N[C@@H]2CC1 Chemical compound C1CC2c(cccc3)c3N[C@@H]2CC1 HYKFPJAARRNNRX-TVKKRMFBSA-N 0.000 description 1
- NOEDTYZIWLUWQD-UHFFFAOYSA-N CC(C)C(CC1)CC(C)C1O Chemical compound CC(C)C(CC1)CC(C)C1O NOEDTYZIWLUWQD-UHFFFAOYSA-N 0.000 description 1
- KJFBXZNNFVLGCZ-AWQFTUOYSA-N CC(C)c(cn[n]1C(N)=N)c1/N=C(\C)/c1cncc(F)c1 Chemical compound CC(C)c(cn[n]1C(N)=N)c1/N=C(\C)/c1cncc(F)c1 KJFBXZNNFVLGCZ-AWQFTUOYSA-N 0.000 description 1
- SCZZFRIRFBVKQP-GFCCVEGCSA-N CC(C)c(cn[n]1c(N[C@H](CC2)Cc3c2[nH]c2ccccc32)n2)c1nc2Cl Chemical compound CC(C)c(cn[n]1c(N[C@H](CC2)Cc3c2[nH]c2ccccc32)n2)c1nc2Cl SCZZFRIRFBVKQP-GFCCVEGCSA-N 0.000 description 1
- JIKPISNVQZKQCV-WHCXFUJUSA-N CC(C)c1c(N)[n](/C(/N[C@H](CC2)Cc3c2[nH]c2ccccc32)=N\C(C)C(C=CN2C)=CC2=O)nc1 Chemical compound CC(C)c1c(N)[n](/C(/N[C@H](CC2)Cc3c2[nH]c2ccccc32)=N\C(C)C(C=CN2C)=CC2=O)nc1 JIKPISNVQZKQCV-WHCXFUJUSA-N 0.000 description 1
- XOAPMXYCEBJDOH-CKAQCJTGSA-N CC(C)c1c(NC([NH+]2[N-]=CN=C2)N=C2N[C@H](CC3)Cc4c3[nH]c3c4cccc3)[n]2nc1 Chemical compound CC(C)c1c(NC([NH+]2[N-]=CN=C2)N=C2N[C@H](CC3)Cc4c3[nH]c3c4cccc3)[n]2nc1 XOAPMXYCEBJDOH-CKAQCJTGSA-N 0.000 description 1
- ORDCUJLCIRQRHN-UHFFFAOYSA-O CC(C)c1c2[NH+](C)C(C(C=C(C=C)N(C)C)=CN)N=C(NC(CC3)Cc4c3[nH]c3c(C)cccc43)[n]2nc1 Chemical compound CC(C)c1c2[NH+](C)C(C(C=C(C=C)N(C)C)=CN)N=C(NC(CC3)Cc4c3[nH]c3c(C)cccc43)[n]2nc1 ORDCUJLCIRQRHN-UHFFFAOYSA-O 0.000 description 1
- IGGOXXITRLZOIJ-CQSZACIVSA-N CC(C)c1c2nc(-[n]3ncnc3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[n]2nc1 Chemical compound CC(C)c1c2nc(-[n]3ncnc3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[n]2nc1 IGGOXXITRLZOIJ-CQSZACIVSA-N 0.000 description 1
- CFCLFRFHWKBOJP-UHFFFAOYSA-N CC(C)c1c2nc(-c3cc(F)cnc3)nc(NC(CC3)CCC3O)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cc(F)cnc3)nc(NC(CC3)CCC3O)[n]2nc1 CFCLFRFHWKBOJP-UHFFFAOYSA-N 0.000 description 1
- UQIBWNHEAHTUEX-UHFFFAOYSA-N CC(C)c1c2nc(-c3cc(F)cnc3)nc(NC(Cc3cncnc3N3)C3=O)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cc(F)cnc3)nc(NC(Cc3cncnc3N3)C3=O)[n]2nc1 UQIBWNHEAHTUEX-UHFFFAOYSA-N 0.000 description 1
- MAFFXBSWBTZXFU-UHFFFAOYSA-N CC(C)c1c2nc(-c3cc(F)cnc3)nc(NCCCO)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cc(F)cnc3)nc(NCCCO)[n]2nc1 MAFFXBSWBTZXFU-UHFFFAOYSA-N 0.000 description 1
- AECXWPYZPBZEPH-QGZVFWFLSA-N CC(C)c1c2nc(-c3cc(F)cnc3)nc(N[C@H](C3)CNc4c3cccc4)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cc(F)cnc3)nc(N[C@H](C3)CNc4c3cccc4)[n]2nc1 AECXWPYZPBZEPH-QGZVFWFLSA-N 0.000 description 1
- CHCLEDHYNRPPAZ-QGZVFWFLSA-N CC(C)c1c2nc(-c3cc(OC)cnc3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[N-]2nc1 Chemical compound CC(C)c1c2nc(-c3cc(OC)cnc3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[N-]2nc1 CHCLEDHYNRPPAZ-QGZVFWFLSA-N 0.000 description 1
- ILTNIXCFKIIOAI-UHFFFAOYSA-N CC(C)c1c2nc(-c3cncc(F)c3)nc(NC3CNC4N=CC=CC4C3)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cncc(F)c3)nc(NC3CNC4N=CC=CC4C3)[n]2nc1 ILTNIXCFKIIOAI-UHFFFAOYSA-N 0.000 description 1
- ILTNIXCFKIIOAI-CRPOECCBSA-N CC(C)c1c2nc(-c3cncc(F)c3)nc(N[C@H]3CNC4N=CC=CC4C3)[n]2nc1 Chemical compound CC(C)c1c2nc(-c3cncc(F)c3)nc(N[C@H]3CNC4N=CC=CC4C3)[n]2nc1 ILTNIXCFKIIOAI-CRPOECCBSA-N 0.000 description 1
- HJVGNIVVESBBPX-MRXNPFEDSA-N CC(C)c1c2nc(C3=CCOC3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[n]2nc1 Chemical compound CC(C)c1c2nc(C3=CCOC3)nc(N[C@H](CC3)Cc4c3[nH]c3ccccc43)[n]2nc1 HJVGNIVVESBBPX-MRXNPFEDSA-N 0.000 description 1
- XAVFPAMTYXGVEJ-UHFFFAOYSA-N CC(CC1)Cc2c1[nH]c(cc1)c2cc1O Chemical compound CC(CC1)Cc2c1[nH]c(cc1)c2cc1O XAVFPAMTYXGVEJ-UHFFFAOYSA-N 0.000 description 1
- RQDUUYIBAAUCKA-LRTDYKAYSA-N CC(N[C@H](CC1)Cc2c1[nH]c1ccccc21)[n]1ncc(C(C)=C)c1/N=C(/c1cc(F)cnc1)\N Chemical compound CC(N[C@H](CC1)Cc2c1[nH]c1ccccc21)[n]1ncc(C(C)=C)c1/N=C(/c1cc(F)cnc1)\N RQDUUYIBAAUCKA-LRTDYKAYSA-N 0.000 description 1
- SIRIJCGXVQXUBB-GOSISDBHSA-N CC(c1c2nc(-c3cncc(F)c3)nc(CN[C@H](CC3)Cc4c3[nH]c3c4C=CCC3)[n]2nc1)=C Chemical compound CC(c1c2nc(-c3cncc(F)c3)nc(CN[C@H](CC3)Cc4c3[nH]c3c4C=CCC3)[n]2nc1)=C SIRIJCGXVQXUBB-GOSISDBHSA-N 0.000 description 1
- YYRFUAJFULKLON-UIDQHGQMSA-N CC/C(/[C@@H](C)NC(N1CCN(C)CC1)=O)=C\N(C(N[C@@H]1CC=C2Nc3ccccc3C2C1)NC(c1cc(F)cnc1)=C)N Chemical compound CC/C(/[C@@H](C)NC(N1CCN(C)CC1)=O)=C\N(C(N[C@@H]1CC=C2Nc3ccccc3C2C1)NC(c1cc(F)cnc1)=C)N YYRFUAJFULKLON-UIDQHGQMSA-N 0.000 description 1
- QRZSJZHAWSEDSS-DEOSSOPVSA-N CN(CC1)CCN1c(nc1)ccc1C1=NC2=CC=N[C@@H]2C(NCc(ccc(Cl)c2)c2Cl)=C1 Chemical compound CN(CC1)CCN1c(nc1)ccc1C1=NC2=CC=N[C@@H]2C(NCc(ccc(Cl)c2)c2Cl)=C1 QRZSJZHAWSEDSS-DEOSSOPVSA-N 0.000 description 1
- ICMZDGXKSHLLCO-UHFFFAOYSA-N COc(ccnc1c(Cl)n2)c1nc2Cl Chemical compound COc(ccnc1c(Cl)n2)c1nc2Cl ICMZDGXKSHLLCO-UHFFFAOYSA-N 0.000 description 1
- QEPVGQBQBGIPGT-LIOMOQFTSA-N C[C@]1(C2)c(cc(cc3)O)c3NC1CC[C@H]2N Chemical compound C[C@]1(C2)c(cc(cc3)O)c3NC1CC[C@H]2N QEPVGQBQBGIPGT-LIOMOQFTSA-N 0.000 description 1
- AFAOGCWLKZYOQH-REBBJWOHSA-N C[IH](N12)=C(CCOC3)C3=C1N=C(/C(/C=C/F)=C/N=[IH])N=C2O Chemical compound C[IH](N12)=C(CCOC3)C3=C1N=C(/C(/C=C/F)=C/N=[IH])N=C2O AFAOGCWLKZYOQH-REBBJWOHSA-N 0.000 description 1
- ZFMTVTUCZCQGEC-UHFFFAOYSA-N C[IH]c1c[nH]c2c1ccc([IH]C)c2 Chemical compound C[IH]c1c[nH]c2c1ccc([IH]C)c2 ZFMTVTUCZCQGEC-UHFFFAOYSA-N 0.000 description 1
- PYFVEIDRTLBMHG-UHFFFAOYSA-N Cc1c(C)[nH]c2c1cccc2 Chemical compound Cc1c(C)[nH]c2c1cccc2 PYFVEIDRTLBMHG-UHFFFAOYSA-N 0.000 description 1
- BOBGJFFADWBUBA-UHFFFAOYSA-N Cc1c[nH]c2c1cccc2C Chemical compound Cc1c[nH]c2c1cccc2C BOBGJFFADWBUBA-UHFFFAOYSA-N 0.000 description 1
- RQGNAHOAQQVKDE-UHFFFAOYSA-N Cc1ccnc(Br)c1N Chemical compound Cc1ccnc(Br)c1N RQGNAHOAQQVKDE-UHFFFAOYSA-N 0.000 description 1
- BCTPIYDQRBCWSX-UHFFFAOYSA-N Fc1c(c(I)c[nH]2)c2ccc1 Chemical compound Fc1c(c(I)c[nH]2)c2ccc1 BCTPIYDQRBCWSX-UHFFFAOYSA-N 0.000 description 1
- MTAODLNXWYIKSO-UHFFFAOYSA-N Fc1ccccn1 Chemical compound Fc1ccccn1 MTAODLNXWYIKSO-UHFFFAOYSA-N 0.000 description 1
- HGZQLNQRMRRKTH-UHFFFAOYSA-N NC(CC1)Cc2c1[nH]c(C=C1)c2CC1O Chemical compound NC(CC1)Cc2c1[nH]c(C=C1)c2CC1O HGZQLNQRMRRKTH-UHFFFAOYSA-N 0.000 description 1
- BODNHESZANDWGC-UHFFFAOYSA-N Nc([n]1nc2)nc(-c3cc(F)cnc3)nc1c2-c1cnn[nH]1 Chemical compound Nc([n]1nc2)nc(-c3cc(F)cnc3)nc1c2-c1cnn[nH]1 BODNHESZANDWGC-UHFFFAOYSA-N 0.000 description 1
- USVMANSYAVTASL-UHFFFAOYSA-N O=C(c([n]1N2)ncc1Br)NC2=O Chemical compound O=C(c([n]1N2)ncc1Br)NC2=O USVMANSYAVTASL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862746277P | 2018-10-16 | 2018-10-16 | |
| US62/746,277 | 2018-10-16 | ||
| PCT/US2019/056455 WO2020081636A1 (en) | 2018-10-16 | 2019-10-16 | Indole ahr inhibitors and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022502476A true JP2022502476A (ja) | 2022-01-11 |
| JPWO2020081636A5 JPWO2020081636A5 (https=) | 2022-10-25 |
| JP2022502476A5 JP2022502476A5 (https=) | 2022-10-25 |
Family
ID=70284697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021521024A Pending JP2022502476A (ja) | 2018-10-16 | 2019-10-16 | インドールａｈｒ阻害剤およびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220144839A1 (https=) |
| EP (1) | EP3867253A4 (https=) |
| JP (1) | JP2022502476A (https=) |
| KR (1) | KR20210110566A (https=) |
| CN (1) | CN113272305A (https=) |
| AU (1) | AU2019360204A1 (https=) |
| BR (1) | BR112021007017A2 (https=) |
| CA (1) | CA3115711A1 (https=) |
| EA (1) | EA202190726A1 (https=) |
| IL (1) | IL282252A (https=) |
| MX (1) | MX2021004245A (https=) |
| SG (1) | SG11202103796TA (https=) |
| WO (1) | WO2020081636A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018195397A2 (en) | 2017-04-21 | 2018-10-25 | Kyn Therapeutics | Indole ahr inhibitors and uses thereof |
| PT4065582T (pt) | 2019-11-26 | 2025-05-22 | Ikena Oncology Inc | Derivados polimórficos do carbazol e utilizações dos mesmos |
| KR20220125323A (ko) | 2020-01-10 | 2022-09-14 | 이케나 온콜로지, 인코포레이티드 | Ahr 억제제 및 이의 용도 |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| US20230227453A1 (en) * | 2020-06-10 | 2023-07-20 | Delix Therapeutics, Inc. | Tricyclic psychoplastogens and uses thereof |
| WO2022078356A1 (zh) * | 2020-10-15 | 2022-04-21 | 山东轩竹医药科技有限公司 | 杂芳环类AhR抑制剂 |
| IL302346A (en) * | 2020-10-28 | 2023-06-01 | Ikena Oncology Inc | Combination of an ahr inhibitor with a pdx inhibitor or doxorubicine |
| KR20230124583A (ko) | 2020-11-23 | 2023-08-25 | 이난타 파마슈티칼스, 인코포레이티드 | 신규한 스피로피롤리딘 유래 항바이러스제 |
| US12540141B2 (en) | 2020-11-23 | 2026-02-03 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN114456178B (zh) * | 2021-01-13 | 2023-06-02 | 北京华森英诺生物科技有限公司 | 四氢嘧啶[1,2-b]吲唑-4-胺类衍生物作为AhR抑制剂的用途及制备方法 |
| CN114805361B (zh) * | 2021-01-17 | 2024-02-20 | 上海凌达生物医药有限公司 | 一类氨基取代的芳香杂环并吡唑类化合物、制备方法和用途 |
| WO2022235605A1 (en) | 2021-05-04 | 2022-11-10 | Enanta Pharmaceuticals, Inc. | Novel macrocyclic antiviral agents |
| WO2023086352A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| WO2023086350A1 (en) | 2021-11-12 | 2023-05-19 | Enanta Pharmaceuticals, Inc. | Alkyne-containing antiviral agents |
| US11919910B2 (en) | 2021-11-12 | 2024-03-05 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11993600B2 (en) | 2021-12-08 | 2024-05-28 | Enanta Pharmaceuticals, Inc. | Saturated spirocyclics as antiviral agents |
| WO2023137007A1 (en) * | 2022-01-11 | 2023-07-20 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 4,6,7-trifluoro-1h-indole-2-carboxylic acid |
| WO2023196307A1 (en) | 2022-04-05 | 2023-10-12 | Enanta Pharmaceuticals, Inc. | Novel spiropyrrolidine derived antiviral agents |
| AU2023249795A1 (en) | 2022-04-08 | 2024-10-17 | Shy Therapeutics, Llc | Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN117624168A (zh) * | 2022-08-19 | 2024-03-01 | 德明药泰生物技术（深圳）有限公司 | 稠环杂环类化合物及其制备方法和应用 |
| AU2023377192A1 (en) | 2022-11-07 | 2025-05-22 | Kyoto University | Nitrogen-containing heterocyclic compound |
| KR20240169284A (ko) | 2023-05-24 | 2024-12-03 | 경희대학교 산학협력단 | AhR-매개 질환의 예방, 개선 또는 치료용 약학적 조성물 |
| WO2025114771A1 (en) | 2023-11-29 | 2025-06-05 | Latvian Institute Of Organic Synthesis | A new class of aryl hydrocarbon receptor antagonists and their optimisation |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006523238A (ja) * | 2003-04-09 | 2006-10-12 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| JP2007523953A (ja) * | 2004-02-25 | 2007-08-23 | シェーリング コーポレイション | キナーゼインヒビターとしてのピラゾロトリアジン |
| JP2012507554A (ja) * | 2008-10-30 | 2012-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 造血幹細胞を増加させる化合物 |
| JP7232244B2 (ja) * | 2017-04-21 | 2023-03-08 | イケナ オンコロジー， インコーポレイテッド | インドールａｈｒ阻害剤およびその使用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721356A (en) * | 1989-09-15 | 1998-02-24 | Gensia, Inc. | Orally active adenosine kinase inhibitors |
| JP2018525345A (ja) * | 2015-07-01 | 2018-09-06 | ノースウェスタン ユニバーシティ | 置換キナゾリン化合物及びグルコセレブロシダーゼ活性の調節のためのその使用 |
| TW201811799A (zh) * | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
-
2019
- 2019-10-16 US US17/281,395 patent/US20220144839A1/en not_active Abandoned
- 2019-10-16 CN CN201980076086.7A patent/CN113272305A/zh active Pending
- 2019-10-16 EA EA202190726A patent/EA202190726A1/ru unknown
- 2019-10-16 WO PCT/US2019/056455 patent/WO2020081636A1/en not_active Ceased
- 2019-10-16 BR BR112021007017-6A patent/BR112021007017A2/pt not_active IP Right Cessation
- 2019-10-16 MX MX2021004245A patent/MX2021004245A/es unknown
- 2019-10-16 JP JP2021521024A patent/JP2022502476A/ja active Pending
- 2019-10-16 SG SG11202103796TA patent/SG11202103796TA/en unknown
- 2019-10-16 CA CA3115711A patent/CA3115711A1/en active Pending
- 2019-10-16 EP EP19873025.1A patent/EP3867253A4/en not_active Withdrawn
- 2019-10-16 AU AU2019360204A patent/AU2019360204A1/en not_active Abandoned
- 2019-10-16 KR KR1020217014753A patent/KR20210110566A/ko not_active Withdrawn
-
2021
- 2021-04-12 IL IL282252A patent/IL282252A/en unknown
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006523238A (ja) * | 2003-04-09 | 2006-10-12 | エクセリクシス， インク． | Ｔｉｅ−２モジュレータと使用方法 |
| JP2007523953A (ja) * | 2004-02-25 | 2007-08-23 | シェーリング コーポレイション | キナーゼインヒビターとしてのピラゾロトリアジン |
| JP2012507554A (ja) * | 2008-10-30 | 2012-03-29 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 造血幹細胞を増加させる化合物 |
| JP7232244B2 (ja) * | 2017-04-21 | 2023-03-08 | イケナ オンコロジー， インコーポレイテッド | インドールａｈｒ阻害剤およびその使用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3867253A4 (en) | 2022-05-18 |
| AU2019360204A1 (en) | 2021-06-03 |
| EA202190726A1 (ru) | 2021-08-19 |
| CA3115711A1 (en) | 2020-04-23 |
| CN113272305A (zh) | 2021-08-17 |
| US20220144839A1 (en) | 2022-05-12 |
| BR112021007017A2 (pt) | 2021-07-13 |
| KR20210110566A (ko) | 2021-09-08 |
| SG11202103796TA (en) | 2021-05-28 |
| EP3867253A1 (en) | 2021-08-25 |
| IL282252A (en) | 2021-05-31 |
| MX2021004245A (es) | 2021-09-08 |
| WO2020081636A1 (en) | 2020-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12077542B2 (en) | Indole AHR inhibitors and uses thereof | |
| JP2022502476A (ja) | インドールａｈｒ阻害剤およびその使用 | |
| US11555026B2 (en) | AHR inhibitors and uses thereof | |
| TWI877770B (zh) | 作為a2a / a2b抑制劑之咪唑并嘧啶及三唑并嘧啶 | |
| JP2022516401A (ja) | Ｉｒａｋ分解剤およびそれらの使用 | |
| JP2021524457A (ja) | Ａ２ａ／ａ２ｂ阻害剤としての縮合ピリミジン誘導体 | |
| BR112019021992B1 (pt) | Compostos inibidores de ahr de indol, composição e usos dos mesmos | |
| EA041983B1 (ru) | Индольные ингибиторы арил-гидрокарбонового рецептора (ahr) и их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221017 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20221017 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20231026 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231117 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240612 |